Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Helal

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Journal of Medicinal Chemistry|April 28, 2020
Synthetic Approaches to New Drugs Approved during 2018Andrew C Flick, Carolyn A Leverett, Hong X Ding, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 31, 2012
Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugsRobert L Walsky, R Scott Obach, Ruth Hyland, et al.
Angewandte Chemie (International Ed. in English)|October 9, 2019
High-Throughput Ligand Screening Enables the Enantioselective Conjugate Borylation of Cyclobutenones to Access Synthetically Versatile Tertiary CyclobutylboronatesHelen A Clement, Michele Boghi, Rory M McDonald, et al.
Organic Letters|January 13, 2018
Introduction of a Crystalline, Shelf-Stable Reagent for the Synthesis of Sulfur(VI) FluoridesHua Zhou, Paramita Mukherjee, Rongqiang Liu, et al.
Bioorganic & Medicinal Chemistry Letters|October 16, 2004
Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's diseaseChristopher J Helal, Mark A Sanner, Christopher B Cooper, et al.
Bioorganic & Medicinal Chemistry Letters|August 25, 2009
Potent and cellularly active 4-aminoimidazole inhibitors of cyclin-dependent kinase 5/p25 for the treatment of Alzheimer's diseaseChristopher J Helal, Zhijun Kang, John C Lucas, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 21, 2016
Preclinical Evaluation of 18F-PF-05270430, a Novel PET Radioligand for the Phosphodiesterase 2A EnzymeLaigao Chen, Nabeel Nabulsi, Mika Naganawa, et al.
Journal of Medicinal Chemistry|May 9, 2013
Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development of a novel phosphodiesterase 2A PET ligandLei Zhang, Anabella Villalobos, Elizabeth M Beck, et al.
Journal of Medicinal Chemistry|July 12, 2012
Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disordersPatrick R Verhoest, Kari R Fonseca, Xinjun Hou, et al.
Journal of Medicinal Chemistry|November 19, 2009
Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategyPatrick R Verhoest, Caroline Proulx-Lafrance, Michael Corman, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Journal of Medicinal Chemistry|April 28, 2020
Synthetic Approaches to New Drugs Approved during 2018Andrew C Flick, Carolyn A Leverett, Hong X Ding, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 31, 2012
Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugsRobert L Walsky, R Scott Obach, Ruth Hyland, et al.
Angewandte Chemie (International Ed. in English)|October 9, 2019
High-Throughput Ligand Screening Enables the Enantioselective Conjugate Borylation of Cyclobutenones to Access Synthetically Versatile Tertiary CyclobutylboronatesHelen A Clement, Michele Boghi, Rory M McDonald, et al.
Organic Letters|January 13, 2018
Introduction of a Crystalline, Shelf-Stable Reagent for the Synthesis of Sulfur(VI) FluoridesHua Zhou, Paramita Mukherjee, Rongqiang Liu, et al.
Bioorganic & Medicinal Chemistry Letters|October 16, 2004
Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's diseaseChristopher J Helal, Mark A Sanner, Christopher B Cooper, et al.
Bioorganic & Medicinal Chemistry Letters|August 25, 2009
Potent and cellularly active 4-aminoimidazole inhibitors of cyclin-dependent kinase 5/p25 for the treatment of Alzheimer's diseaseChristopher J Helal, Zhijun Kang, John C Lucas, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 21, 2016
Preclinical Evaluation of 18F-PF-05270430, a Novel PET Radioligand for the Phosphodiesterase 2A EnzymeLaigao Chen, Nabeel Nabulsi, Mika Naganawa, et al.
Journal of Medicinal Chemistry|May 9, 2013
Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development of a novel phosphodiesterase 2A PET ligandLei Zhang, Anabella Villalobos, Elizabeth M Beck, et al.
Journal of Medicinal Chemistry|July 12, 2012
Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disordersPatrick R Verhoest, Kari R Fonseca, Xinjun Hou, et al.
Journal of Medicinal Chemistry|November 19, 2009
Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategyPatrick R Verhoest, Caroline Proulx-Lafrance, Michael Corman, et al.
Pageof 4